Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024

Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards.

The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to moderate atopic dermatitis (AD), addresses a need in dermatology for a potent, non-irritating topical solution for chronic skin conditions. According to a press release from the manufacturer, ZORYVE is recognized as a next-generation phosphodiesterase-4 (PDE4) inhibitor and has gained attention for its unique delivery of roflumilast in a proprietary formulation free from excipients, irritants, or sensitizers. It was approved by the FDA in July 2024 for use in individuals six and older.

“This prestigious award from Glamour is a testament to the exceptional work of our research and development and technical operations teams to formulate ZORYVE, a highly selective and potent PDE4 inhibitor," Frank Watanabe, president and CEO of Arcutis, said in a press release. "As a result, ZORYVE is an effective, well tolerated, moisturizing topical that can be applied anywhere on the body for any duration. ZORYVE delivers its active ingredient in a formulation that is free of any excipients, irritants, or sensitizers that could further compromise a patient’s skin barrier, which is critical for chronic skin conditions like eczema."

Source: Arcutis press release. November 13, 2024.